Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice
Open Access
- 27 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e60493
Abstract
Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer’s disease in addition to infectious diseases. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking an adequate humoral immune response from B cells while avoiding T cell activation in response to self. Although the vaccine targeting angiotensin II (Ang II) is efficient in rodents and humans, little is known regarding the immunological activation and safety of the vaccine. In this study, we evaluated the efficiency and safety of an Ang II peptide vaccine in mice. Immunization with Ang II conjugated to keyhole limpet hemocyanin (KLH) successfully induced the production of anti-Ang II antibody, which blocked Ang II signaling in human aortic smooth muscle cells. However, Ang II itself did not activate T cells, as assessed by the proliferation and lymphokine production of T cells in immunized mice, whereas KLH activated T cells. In an Ang II-infused model, the non-immunized mice showed high blood pressure (BP), whereas the immunized mice (Ang II-KLH) showed a significant decrease in systolic BP, accompanied by significant reductions in cardiac hypertrophy and fibrosis. Importantly, anti-Ang II antibody titer was not elevated even after the administration of large amounts of Ang II, indicating that Ang II itself boosted antibody production, most likely due to less activation of T cells. In addition, no accumulation of inflammatory cells was observed in immunized mice, because endogenous Ang II would not activate T cells after immunization with Ang II-KLH. Taken together, these data indicate that vaccines targeting Ang II might be effective to decrease high BP and prevent cardiovascular complications without severe side effects.Keywords
This publication has 36 references indexed in Scilit:
- Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Co-administration of a CpG adjuvant (VaxImmuneTM, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and miceHuman Vaccines, 2009
- The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in ratsJournal of Clinical Investigation, 2008
- Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesisJournal of Vascular Surgery, 2007
- A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityJournal Of Hypertension, 2007
- Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjectsClinical Science, 2004
- Anti‐Aβ: The good, the bad, and the unforeseenJournal of Neuroscience Research, 2003
- Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in manBritish Journal of Clinical Pharmacology, 2003
- Antibodies to Renin as Proof of the Pathogenesis of Sustained Renal HypertensionCirculation, 1958
- Studies on Renin AntibodiesCirculation, 1958